A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
← catalyst calendarNCT06937229 · readout in 1,037 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
650estimated
Sites
256
Countries
Argentina, Brazil, Bulgaria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-02 | actual | When the study began enrolling |
| Primary completion | 2029-06-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer Disease
- Agitation
Interventions
- Drug: KarXT — also filed as Xanomeline and Trospium Chloride capsule, BMS-986510
- Drug: KarX-EC — also filed as Xanomeline enteric capsules, BMS-986519
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to approximately Week 30
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed